Search

Displaying results 6441 - 6450 of 10000 in total
  1. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

  2. Drug

    Ochromycinone

    go.drugbank.com/drugs/DB15644
    Investigational

    Ochromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).

  3. Drug

    Puromycin

    go.drugbank.com/drugs/DB08437
    Experimental

    Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. … Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.

  4. Drug

    Nelipepimut-S

    go.drugbank.com/drugs/DB06226
    Investigational

  5. Drug

    Monlunabant

    go.drugbank.com/drugs/DB21537
    Investigational

    Monlunabant is under investigation in clinical trial NCT06542536 (A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight … The usage of the INN stem '-nabant' in the name indicates that Monlunabant is a cannabinoid receptor antagonist.

  6. Drug

    Viper antivenom

    go.drugbank.com/drugs/DB14114
    ApprovedInvestigational

    ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

  7. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    [A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,

  8. Drug

    Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

    go.drugbank.com/drugs/DB15728
    Experimental

    The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties. … In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic.

    Synonyms: Allogeneic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media, Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
  9. Drug

    Vatalanib

    go.drugbank.com/drugs/DB04879
    Investigational

    Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

  10. Drug

    Rebastinib

    go.drugbank.com/drugs/DB13005
    Investigational

    Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.